Elster Dana, Jaenicke Laura A, Eilers Martin, von Eyss Björn
a Leibniz Institute on Aging, Fritz Lipmann Institute e.V. , Jena , Germany.
b Theodor Boveri Institute, Biocenter, University of Würzburg , Würzburg Germany.
Cell Cycle. 2016 Oct;15(19):2551-2556. doi: 10.1080/15384101.2016.1207837. Epub 2016 Jul 19.
c-Myc (MYC) is an oncogenic transcription factor that is commonly overexpressed in a wide variety of human tumors. In breast cancer, MYC has recently been linked to the triple-negative subtype, a subtype that lacks any targeted therapy. Previously, we demonstrated that MYC behaves as a potent repressor of YAP and TAZ, 2 transcriptional coactivators that function as downstream transducers of the Hippo pathway. In this previous study, MYC repressed YAP/TAZ not only in primary breast epithelial cells but also in mouse models of triple-negative tumors. Here, we extend our previous bioinformatic and experimental analyses and demonstrate that MYC deregulation in primary breast epithelial cells leads to a robust repression of TEAD transcription factor activity, the transcription factor family mainly responsible for YAP/TAZ recruitment. Surprisingly, we find that MYC and TEAD activity is able to stratify different breast cancer subtypes in large panels of breast cancer patients. Thus, a deep understanding of the MYC-YAP/TAZ circuitry might yield new insights into the establishment and maintenance of specific breast cancer subtypes.
c-Myc(MYC)是一种致癌转录因子,在多种人类肿瘤中通常过度表达。在乳腺癌中,MYC最近与三阴性亚型相关联,该亚型缺乏任何靶向治疗方法。此前,我们证明MYC作为YAP和TAZ的强效抑制因子,YAP和TAZ是两种转录共激活因子,作为Hippo信号通路的下游转导分子发挥作用。在之前的这项研究中,MYC不仅在原发性乳腺上皮细胞中,而且在三阴性肿瘤的小鼠模型中均抑制YAP/TAZ。在此,我们扩展了之前的生物信息学和实验分析,并证明原发性乳腺上皮细胞中MYC失调会导致TEAD转录因子活性受到强烈抑制,TEAD转录因子家族主要负责YAP/TAZ的招募。令人惊讶的是,我们发现MYC和TEAD活性能够在大量乳腺癌患者中区分不同的乳腺癌亚型。因此,深入了解MYC-YAP/TAZ信号通路可能会为特定乳腺癌亚型的建立和维持带来新的见解。